Compare Adaptive Biotechnologies Corp (ADPT) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Marsh & McLennan Companies, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Marsh & McLennan Companies, Inc. trades at $179.07 (market cap $85.76B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 25.8× Adaptive Biotechnologies Corp's market cap, and Marsh & McLennan Companies, Inc. pays a 2.02% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MRSH | |
|---|---|---|
Market Cap | $3.33B | $85.76B |
Sector | Health | Financials |
52-Week High | $22.37 | $214.71 |
52-Week Low | $10.24 | $157.32 |
Enterprise Value | $3.19B | $106.60B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Marsh (MRSH) trades at $178.00, showing modest daily weakness (-0.3%) but maintaining a bullish technical trend above key support levels. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations, and robust profitability metrics with 14.26% net income margin and 27.42% ROE. Recent acquisition of TriBridge Partners strengthens advisory capabilities while dividend payments provide shareholder returns.
Marsh presents a compelling investment case with analyst consensus target of $192.00 offering 7.9% upside potential. The stock trades at reasonable valuation multiples (P/E 21.84, P/S 3.12) for its quality profile, though rising costs and premium valuation warrant monitoring. Institutional sentiment remains positive with 11 buy ratings outweighing 1 sell recommendation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
